Dynavax Technologies Corporation
Dynavax Technologies Corporation
2929 Seventh Street, Suite 100
Berkeley, CA 94710
Phone: (510) 848-5100Website: https://www.dynavax.com/Careers: www.dynavax.com/careers
Latest news
- Dynavax Announces FDA Approval of Heplisav-B for Prevention of Hepatitis B in Adults
9 November 2017 - Dynavax Provides U.S. Regulatory Update on Heplisav-B Following FDA Advisory Committee Meeting
3 August 2017 - Dynavax Announces FDA Advisory Committee Vote in Favor of Heplisav-B
28 July 2017 - Dynavax Receives Complete Response Letter from U.S. FDA for Biologics License Application for Heplisav-B
14 November 2016 - Dynavax Provides Regulatory Update on Heplisav-B
4 October 2016 - Dynavax Reports Feedback From FDA Meeting Regarding Heplisav Biologic License Application
10 June 2013 - Dynavax Receives FDA Complete Response Letter on Heplisav Biologic License Application
25 February 2013 - Dynavax Announces FDA Advisory Committee Meeting Outcome for Heplisav
16 November 2012 - Dynavax Announces FDA Advisory Committee to Review Heplisav
29 August 2012 - Dynavax Announces FDA Acceptance of Heplisav BLA
27 June 2012
Drugs Associated with Dynavax Technologies Corporation
Dynavax Technologies Corporation manufactures, markets and/or distributes 1 drug in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Heplisav-B
Generic name: hepatitis b adult vaccine Drug class: viral vaccines |
||
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||
